Comparing the Effect of Atypical and Conventional Antipsychotics on Lipid Profile

Document Type : Original Article (s)

Authors

1 Assistant Professor, Isfahan Cardiovascular Research Center, Isfahan Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran

2 Research Assistant, Isfahan Cardiovascular Research Center, Isfahan Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran

3 Associate Professor, Psychosomatic Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

4 Cardiac Rehabilitation Research Center, Isfahan Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran

5 Associate Professor, Cardiac Rehabilitation Research Center, Isfahan Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: Patients with schizophrenia receiving antipsychotic drugs are highly at risk of metabolic disorders such as weight gain, dyslipidemia, and insulin resistance. This study was designed to compare the effect of atypical and conventional antipsychotics on lipid profile.Methods: 128 patients with schizophrenia were divided in two groups. One of the groups received one type of atypical antipsychotic drugs while the other got one type of conventional ones. None of the groups had used any other antipsychotic drugs during the past year. Demographic data and food frequency questionnaire were completed by each participant. Serum triglyceride, total cholesterol (TC), high-density lipoprotein (HDL) and low-density lipoprotein (LDL) cholesterols, and apolipoprotein A and B (Apo A and B) were recorded. Student’s t test was used for statistical analysis.Findings: The two groups were similar in age, gender, duration of illness, period of drug consumption, and age at onset of illness. Patients in the atypical group used clozapine and risperidone (46.9%) more than olanzapine; while in the conventional group, 81.3% of patients used phenothiazines. Our data showed a significantly higher mean in TC (P = 0.01), LDL (P = 0.03), and Apo B (P = 0.01) in conventional group.Conclusion: In patients with schizophrenia, lipid profile was higher in both atypical and conventional antipsychotic users, especially in conventional drug users. 

Keywords

References

  1. Wen F, Tan J. Effects of phenothiazine drugs on serum levels of apolipoproteins and lipoproteins in schizophrenic subjects. Acta Pharmacol Sin 2003; 24(10): 1001-5.
  2. Meyer JM, Koro CE. The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr Res 2004; 70(1): 1-17.
  3. Crossley NA, Constante M, McGuire P, Power P. Efficacy of atypical v. typical antipsychotics in the treatment of early psychosis: meta-analysis. Br J Psychiatry 2010; 196(6): 434-9.
  4. Baranyi A, Yazdani R, Haas-Krammer A, Stepan A, Kapfhammer HP, Rothenhausler HB. Atypical antipsychotics and metabolic syndrome. Wien Med Wochenschr 2007; 157(11-12): 255-70. [In German].
  5. Koro CE, Fedder DO, L'Italien GJ, Weiss S, Magder LS, Kreyenbuhl J, et al. An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients. Arch Gen Psychiatry 2002; 59(11): 1021-6.
  6. Lindenmayer JP, Czobor P, Volavka J, Citrome L, Sheitman B, McEvoy JP, et al. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry 2003; 160(2): 290-6.
  7. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-IVTR: text revision. 4th ed. Washington, DC: American Psychiatric Pub; 2000.
  8. Cade JE, Burley VJ, Warm DL, Thompson RL, Margetts BM. Food-frequency questionnaires: a review of their design, validation and utilisation. Nutr Res Rev 2004; 17(1): 5-22.
  9. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18(6): 499-502.
  10. Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000; 321(7273): 1371-6.
  11. Saari K, Koponen H, Laitinen J, Jokelainen J, Lauren L, Isohanni M, et al. Hyperlipidemia in persons using antipsychotic medication: a general population-based birth cohort study. J Clin Psychiatry 2004; 65(4): 547-50.
  12. Henderson DC, Cagliero E, Gray C, Nasrallah RA, Hayden DL, Schoenfeld DA, et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study. Am J Psychiatry 2000; 157(6): 975-81.
  13. Baymiller SP, Ball P, McMahon RP, Buchanan RW. Serum glucose and lipid changes during the course of clozapine treatment: the effect of concurrent beta-adrenergic antagonist treatment. Schizophr Res 2003; 59(1): 49-57.
Journal of Isfahan Medical School
Volume 32, Issue 319 - Serial Number 319
November and December 2015
Pages 2394-2400

Files

History

  • Receive Date: 08 July 2014
  • Revise Date: 01 November 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics